Motor Neuron Disease — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Microbiome and metabolites impact enteric and central nervous systems in ALS.
Walton Erykah I et al. — Gut microbes (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42374626/
- 2.
Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy-Advances through 2026.
Morimoto Satoru et al. — Regenerative therapy (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42359165/
- 3.
The role of SUMOylation in regulating proteins that drive neuronal disease progression.
Sidharth Aditya et al. — Biochemistry and biophysics reports (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42395866/
- 4.
Deletion of exon 2 in ALS-linked
Pant Devesh C et al. — Life science alliance (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42392979/
- 5.
Unravelling the Significance of Cystatin C and Bunina Bodies in Amyotrophic Lateral Sclerosis Pathogenesis.
Granger Sarah M et al. — Neuropathology and applied neurobiology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42373582/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
- 2.
Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease
Recruiting — Na — University of Melbourne
https://clinicaltrials.gov/study/NCT05136222
- 3.
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Recruiting — Phase 1 — Regeneron Pharmaceuticals
https://clinicaltrials.gov/study/NCT06351592
- 4.
Functional Outcomes and Control Using Synchron BCI - Australia
Recruiting — Na — Synchron, Inc.
https://clinicaltrials.gov/study/NCT07533903
- 5.
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Recruiting — Phase 2 — Mario Negri Institute for Pharmacological Research
https://clinicaltrials.gov/study/NCT06126315
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Motor Neuron Disease
Motor neuron disease (MND), also known as ALS, is a progressive neurodegenerative condition that destroys the nerve cells controlling movement, leading to muscle weakness, paralysis, and eventually respiratory failure. Most cases are fatal within 2-5 years of diagnosis. Riluzole and edaravone are approved treatments; antisense oligonucleotide therapies targeting SOD1 and FUS are transforming outcomes for genetic subtypes.
Most Recent Research
Amyotrophic lateral sclerosis (ALS) has been linked to gastrointestinal symptoms and alterations in the gut microbiota. The enteric nervous system (ENS) coordinates intestinal function and sits at the host-microbe interface. The mechanisms by which luminal changes relay to the central nervous system (CNS), where motor neurons reside, have yet to be completely defined. In this narrative review, we first present evidence from ALS patient cohorts and preclinical models alongside mechanistic studies of infection, dysbiosis, and related neurodegenerative diseases to discuss how the microbiota and its metabolites may affect the ENS and CNS in ALS. Next, we propose a plausible mechanism of ALS pathogenesis through the gut-microbiome-brain axis. We further offer a summary of clinical trials that have studied the impacts of the microbiota on human ALS. Finally, we discuss future directions for studies of microbiota-ENS-CNS interactions in ALS. Better understanding of the dynamic interactions among the microbiota, microbial metabolites, neuroactive metabolites, and inflammation through the ENS/CNS in ALS will provide innovative insights into ALS prevention and treatment.
Common Questions
What is Motor Neuron Disease?
Motor neuron disease (MND), also known as ALS, is a progressive neurodegenerative condition that destroys the nerve cells controlling movement, leading to muscle weakness, paralysis, and eventually respiratory failure. Most cases are fatal within 2-5 years of diagnosis. Riluzole and edaravone are approved treatments; antisense oligonucleotide therapies targeting SOD1 and FUS are transforming outcomes for genetic subtypes.
How many clinical trials are available for Motor Neuron Disease?
RareWays currently indexes 792 clinical trials for Motor Neuron Disease, of which 199 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Motor Neuron Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Motor Neuron Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.